PneumoWave

The company's core technology is a wearable biosensor that continuously tracks respiratory patterns in real-time. This data is transmitted wirelessly to a platform that uses proprietary algorithms and machine learning to analyze the information and generate digital biomarkers. The system is designed to detect life-threatening changes in breathing, such as respiratory depression, and issue alerts to the user, caregivers, or emergency services to enable timely intervention. The primary focus is on preventing deaths from Opioid-Induced Respiratory Depression (OIRD), a major cause of accidental deaths, and managing other conditions like Chronic Obstructive Pulmonary Disease (COPD).

PneumoWave's business model targets healthcare providers, researchers, and patients, with a commercial roadmap that included a planned US clinic launch in 2026. The company has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) and is undergoing clinical validation with a regulatory submission anticipated in early 2024. PneumoWave has raised a total of $12.3M over two funding rounds, including a £7.5 million ($9.16M) Series A round in 2022. Key investors include the Scottish National Investment Bank, Scottish Enterprise, Equity Gap, and Alba Equity.